The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor

Cancer Cell

Volumn 10, Issue 2, 2006, Pages 133-143

  Sodhi, Akrit ^c,d   Chaisuparat, Risa ^a   Hu, Jiadi ^a   Ramsdell, Amanda K ^c   Manning, Brendan D ^e   Sausville, Edward A ^b   Sawai, Earl T ^d   Molinolo, Alfredo ^c   Gutkind, J Silvio ^c   Montaner, Silvia ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e HARVARD UNIVERSITY   (United States)

Author keywords

CELLCYCLE

Indexed keywords

G PROTEIN COUPLED RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; RAPAMYCIN; TUBERIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CARCINOGENICITY; CELL TRANSFORMATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN HERPESVIRUS 8; HUMAN TISSUE; KAPOSI SARCOMA; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; VASCULAR TUMOR;

HUMAN HERPESVIRUS 8;

EID: 33746832011     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2006.05.026     Document Type: Article

References (65)

1. Aoki M., Blazek E., and Vogt P.K. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc. Natl. Acad. Sci. USA 98 (2001) 136-141
2. Arvanitakis L., Geras-Raaka E., Varma A., Gershengorn M.C., and Cesarman E. Human herpesvirus KSHV encodes a constitutively active G-protein- coupled receptor linked to cell proliferation. Nature 385 (1997) 347-350
3. Bais C., Santomasso B., Coso O., Arvanitakis L., Raaka E.G., Gutkind J.S., Asch A.S., Cesarman E., Gershengorn M.C., Mesri E.A., and Gerhengorn M.C. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 391 (1998) 86-89
4. Brugarolas J.B., Vazquez F., Reddy A., Sellers W.R., and Kaelin Jr. W.G. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4 (2003) 147-158
5. Campistol J.M., Gutierrez-Dalmau A., and Torregrosa J.V. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 77 (2004) 760-762
6. Cesarman E., Nador R.G., Bai F., Bohenzky R.A., Russo J.J., Moore P.S., Chang Y., and Knowles D.M. Kaposi's sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologs which are expressed in Kaposi's sarcoma and malignant lymphoma. J. Virol. 70 (1996) 8218-8223
7. Chang Y., Cesarman E., Pessin M.S., Lee F., Culpepper J., Knowles D.M., and Moore P.S. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266 (1994) 1865-1869
8. Cheung M.C., Pantanowitz L., and Dezube B.J. AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy. Oncologist 10 (2005) 412-426
9. Chiou C.J., Poole L.J., Kim P.S., Ciufo D.M., Cannon J.S., ap Rhys C.M., Alcendor D.J., Zong J.C., Ambinder R.F., and Hayward G.S. Patterns of gene expression and a transactivation function exhibited by the vGCR (ORF74) chemokine receptor protein of Kaposi's sarcoma- associated herpesvirus. J. Virol. 76 (2002) 3421-3439
10. Couty J.P., Geras-Raaka E., Weksler B.B., and Gershengorn M.C. Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor signals through multiple pathways in endothelial cells. J. Biol. Chem. 276 (2001) 33805-33811
11. Dan H.C., Sun M., Yang L., Feldman R.I., Sui X.M., Ou C.C., Nellist M., Yeung R.S., Halley D.J., Nicosia S.V., et al. Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J. Biol. Chem. 277 (2002) 35364-35370
12. Davies S.P., Reddy H., Caivano M., and Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351 (2000) 95-105
13. Dourmishev L.A., Dourmishev A.L., Palmeri D., Schwartz R.A., and Lukac D.M. Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis. Microbiol. Mol. Biol. Rev. 67 (2003) 175-212
14. Downward J. PI 3-kinase, Akt and cell survival. Semin. Cell Dev. Biol. 15 (2004) 177-182
15. Edinger A.L., Linardic C.M., Chiang G.G., Thompson C.B., and Abraham R.T. Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Cancer Res. 63 (2003) 8451-8460
16. Garami A., Zwartkruis F.J., Nobukuni T., Joaquin M., Roccio M., Stocker H., Kozma S.C., Hafen E., Bos J.L., and Thomas G. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell 11 (2003) 1457-1466
17. Gingras A.C., Kennedy S.G., O'Leary M.A., Sonenberg N., and Hay N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev. 12 (1998) 502-513
18. Guo H.G., Sadowska M., Reid W., Tschachler E., Hayward G., and Reitz M. Kaposi's sarcoma-like tumors in a human herpesvirus 8 ORF74 transgenic mouse. J. Virol. 77 (2003) 2631-2639
19. Ho H.H., Ganeshalingam N., Rosenhouse-Dantsker A., Osman R., and Gershengorn M.C. Charged residues at the intracellular boundary of transmembrane helices 2 and 3 independently affect constitutive activity of Kaposi's sarcoma- associated herpesvirus G protein-coupled receptor. J. Biol. Chem. 276 (2001) 1376-1382
20. Huang S., Bjornsti M.A., and Houghton P.J. Rapamycins: mechanism of action and cellular resistance. Cancer Biol. Ther. 2 (2003) 222-232
21. Hudson C.C., Liu M., Chiang G.G., Otterness D.M., Loomis D.C., Kaper F., Giaccia A.J., and Abraham R.T. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 22 (2002) 7004-7014
22. Humar R., Kiefer F.N., Berns H., Resink T.J., and Battegay E.J. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J. 16 (2002) 771-780
23. Im E., von Lintig F.C., Chen J., Zhuang S., Qui W., Chowdhury S., Worley P.F., Boss G.R., and Pilz R.B. Rheb is in a high activation state and inhibits B-Raf kinase in mammalian cells. Oncogene 21 (2002) 6356-6365
24. Inoki K., Li Y., Zhu T., Wu J., and Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4 (2002) 648-657
25. Inoki K., Li Y., Xu T., and Guan K.L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17 (2003) 1829-1834
26. Inoki K., Corradetti M.N., and Guan K.L. Dysregulation of the TSC-mTOR pathway in human disease. Nat. Genet. 37 (2005) 19-24
27. Inukai N., Yamaguchi Y., Kuraoka I., Yamada T., Kamijo S., Kato J., Tanaka K., and Handa H. A novel hydrogen peroxide-induced phosphorylation and ubiquitination pathway leading to RNA polymerase II proteolysis. J. Biol. Chem. 279 (2004) 8190-8195
28. Jensen K.K., Manfra D.J., Grisotto M.G., Martin A.P., Vassileva G., Kelley K., Schwartz T.W., and Lira S.A. The human herpes virus 8-encoded chemokine receptor is required for angioproliferation in a murine model of Kaposi's sarcoma. J. Immunol. 174 (2005) 3686-3694
29. Kwiatkowski D.J., Zhang H., Bandura J.L., Heiberger K.M., Glogauer M., el-Hashemite N., and Onda H. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum. Mol. Genet. 11 (2002) 525-534
30. Luo J., Manning B.D., and Cantley L.C. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4 (2003) 257-262
31. Majumder P.K., Febbo P.G., Bikoff R., Berger R., Xue Q., McMahon L.M., Manola J., Brugarolas J., McDonnell T.J., Golub T.R., et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 10 (2004) 594-601
32. Manning B.D. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J. Cell Biol. 167 (2004) 399-403
33. Manning B.D., and Cantley L.C. United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem. Soc. Trans. 31 (2003) 573-578
34. Manning B.D., Tee A.R., Logsdon M.N., Blenis J., and Cantley L.C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell 10 (2002) 151-162
35. Mayerhofer M., Valent P., Sperr W.R., Griffin J.D., and Sillaber C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 100 (2002) 3767-3775
36. Mitsuyasu R.T. Update on the pathogenesis and treatment of Kaposi sarcoma. Curr. Opin. Oncol. 12 (2000) 174-180
37. Montaner S., Ramos A., Perona R., Esteve P., Carnero A., and Lacal J.C. Overexpression of PKC zeta in NIH3T3 cells does not induce cell transformation nor tumorigenicity and does not alter NF kappa B activity. Oncogene 10 (1995) 2213-2220
38. Montaner S., Sodhi A., Pece S., Mesri E.A., and Gutkind J.S. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor promotes endothelial cell survival through the activation of Akt/protein kinase B. Cancer Res. 61 (2001) 2641-2648
39. Montaner S., Sodhi A., Molinolo A., Bugge T.H., Sawai E.T., He Y., Li Y., Ray P.E., and Gutkind J.S. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 3 (2003) 23-36
40. Montaner S., Sodhi A., Servitja J.M., Ramsdell A.K., Barac A., Sawai E.T., and Gutkind J.S. The small GTPase Rac1 links the Kaposi sarcoma-associated herpesvirus vGPCR to cytokine secretion and paracrine neoplasia. Blood 104 (2004) 2903-2911
41. Montaner S., Sodhi A., Ramsdell A.K., Martin D., Hu J., Sawai E.T., and Gutkind J.S. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor as a therapeutic target for the treatment of Kaposi's sarcoma. Cancer Res. 66 (2006) 168-174
42. Moore P.S., and Chang Y. Molecular virology of Kaposi's sarcoma-associated herpesvirus. Philos. Trans. R. Soc. Lond. B Biol. Sci. 356 (2001) 499-516
43. Munshi N., Ganju R.K., Avraham S., Mesri E.A., and Groopman J.E. Kaposi's sarcoma-associated herpesvirus-encoded G protein-coupled receptor activation of c-jun amino-terminal kinase/stress-activated protein kinase and lyn kinase is mediated by related adhesion focal tyrosine kinase/proline-rich tyrosine kinase 2. J. Biol. Chem. 274 (1999) 31863-31867
44. Onda H., Lueck A., Marks P.W., Warren H.B., and Kwiatkowski D.J. Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J. Clin. Invest. 104 (1999) 687-695
45. Pantanowitz L., and Dezube B.J. Advances in the pathobiology and treatment of Kaposi sarcoma. Curr. Opin. Oncol. 16 (2004) 443-449
46. Parsons R. Human cancer, PTEN and the PI-3 kinase pathway. Semin. Cell Dev. Biol. 15 (2004) 171-176
47. Pati S., Cavrois M., Guo H.G., Foulke Jr. J.S., Kim J., Feldman R.A., and Reitz M. Activation of NF-kappaB by the human herpesvirus 8 chemokine receptor ORF74: evidence for a paracrine model of Kaposi's sarcoma pathogenesis. J. Virol. 75 (2001) 8660-8673
48. Polson A.G., Wang D., DeRisi J., and Ganem D. Modulation of host gene expression by the constitutively active G protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus. Cancer Res. 62 (2002) 4525-4530
49. Potter C.J., Pedraza L.G., and Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell Biol. 4 (2002) 658-665
50. Richardson C.J., Schalm S.S., and Blenis J. PI3-kinase and TOR: PIKTORing cell growth. Semin. Cell Dev. Biol. 15 (2004) 147-159
51. Sabers C.J., Martin M.M., Brunn G.J., Williams J.M., Dumont F.J., Wiederrecht G., and Abraham R.T. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J. Biol. Chem. 270 (1995) 815-822
52. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304 (2004) 554
53. Schmelzle T., and Hall M.N. TOR, a central controller of cell growth. Cell 103 (2000) 253-262
54. Schwarz M., and Murphy P.M. Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor constitutively activates NF-kappa B and induces proinflammatory cytokine and chemokine production via a C-terminal signaling determinant. J. Immunol. 167 (2001) 505-513
55. Sodhi A., Montaner S., Patel V., Zohar M., Bais C., Mesri E.A., and Gutkind J.S. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res. 60 (2000) 4873-4880
56. Sodhi A., Montaner S., and Gutkind J.S. Does dysregulated expression of a deregulated viral GPCR trigger Kaposi's sarcomagenesis?. FASEB J. 18 (2004) 422-427
57. Sodhi A., Montaner S., and Gutkind J.S. Viral hijacking of G-protein-coupled-receptor signalling networks. Nat. Rev. Mol. Cell Biol. 5 (2004) 998-1012
58. Sodhi A., Montaner S., Patel V., Gomez-Roman J.J., Li Y., Sausville E.A., Sawai E.T., and Gutkind J.S. Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor. Proc. Natl. Acad. Sci. USA 101 (2004) 4821-4826
59. Stallone G., Schena A., Infante B., Di Paolo S., Loverre A., Maggio G., Ranieri E., Gesualdo L., Schena F.P., and Grandaliano G. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N. Engl. J. Med. 352 (2005) 1317-1323
60. Tee A.R., Manning B.D., Roux P.P., Cantley L.C., and Blenis J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 13 (2003) 1259-1268
61. Thompson J.E., and Thompson C.B. Putting the rap on Akt. J. Clin. Oncol. 22 (2004) 4217-4226
62. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2 (2002) 489-501
63. Wendel H.G., De Stanchina E., Fridman J.S., Malina A., Ray S., Kogan S., Cordon-Cardo C., Pelletier J., and Lowe S.W. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428 (2004) 332-337
64. Wislez M., Spencer M.L., Izzo J.G., Juroske D.M., Balhara K., Cody D.D., Price R.E., Hittelman W.N., Wistuba I.I., and Kurie J.M. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res. 65 (2005) 3226-3235
65. Yang T.Y., Chen S.C., Leach M.W., Manfra D., Homey B., Wiekowski M., Sullivan L., Jenh C.H., Narula S.K., Chensue S.W., and Lira S.A. Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma. J. Exp. Med. 191 (2000) 445-454